Establishment of a Prospective Clinical-biological Database

Last updated: February 11, 2025
Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Overall Status: Active - Recruiting

Phase

N/A

Condition

Sarcoma

Treatment

Paraffin tissue samples

blood sample

Clinical Study ID

NCT04458792
ICM-BDD 2016/03
  • Ages > 18
  • All Genders

Study Summary

A Clinical and Biological Database will provide to the scientific community a collection of blood and tissues with clinical data to improve knowledge about cancer and help to develope new cancer treatments. This database is specific to Sarcoma

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • men or women > 18 years

  • Patient treated by surgery for : a primitive sarcoma and/or local relapse sarcomaand/or metastatic localisation of sarcoma

  • patient accepted blood sample

  • patient treated by radiotherapy before or after the surgery

  • Patient signed informed consent

Exclusion

Exclusion Criteria:

  • Patient not affiliated to french Social Protection system

  • Patient under guardianship

  • Patient unable to understand or comply with study instructions or requirements forpsychological, family, social or geographical reasons

  • Pregnancy and/or feeding

  • Patient take care in an Emergency Situation

Study Design

Total Participants: 450
Treatment Group(s): 2
Primary Treatment: Paraffin tissue samples
Phase:
Study Start date:
November 01, 2016
Estimated Completion Date:
November 30, 2032

Study Description

Liposarcomas (LPS) are soft tissue tumours of mesenchymal origin. The most common histological subtypes, represented by well differenciated Lipsarcomas (WD-LPS) and dedifferenciated (DD-LPS), are characterized by the quasi-systematic amplification of the q13-15 of chromosome 12 containing the Mdm2 gene.

The systematic amplification of the Mdm2 gene is such that it is used clinically to distinguish WD/DD-LPS from other types of sarcomas. These observations raise key questions about the high selection pressure that leads to the almost systematic amplification of Mdm2 during the development of these LPS.

Mdm2 is an oncoprotein whose roles in p53 tumour suppressor degradation are broadly described. However, the different inhibitors targeting this interaction were disappointing in clinical trials.

Recently a team from the U1194 INSERM unit of the IRCM which collaborates in this project showed by a pan-genomics analysis, that Mdm2 is recruited to chromatin within a multiproteic complex having as target a transcriptional program involved in the metabolism and in particular in the biosynthesis of the serin.

This clinical-biological basis will allow the continuation of this research project on liposarcomas and the development of new research projects on other histological types of sarcomas.

Connect with a study center

  • Icm Val D'Aurelle

    Montpellier, Herault 34298
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.